Daniel Appelbaum to Male
This is a "connection" page, showing publications Daniel Appelbaum has written about Male.
Connection Strength
0.191
-
Comparison of Measurement and Prognostic Power of SUV Between High-Definition and Standard PET Imaging in Non-Small Cell Lung Cancer Patients. J Nucl Med Technol. 2024 Sep 05; 52(3):229-233.
Score: 0.049
-
The utility of the nonattenuation corrected 18F-FDG PET images in the characterization of solitary pulmonary lesions. Nucl Med Commun. 2010 Nov; 31(11):945-51.
Score: 0.019
-
Positron emission tomography (PET) used to image subclinical inflammation associated with ulcerative colitis (UC) in remission. Inflamm Bowel Dis. 2009 May; 15(5):750-5.
Score: 0.017
-
MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocr Relat Cancer. 2024 Nov 01; 31(11).
Score: 0.012
-
Delayed 99mTc-labeled erythrocyte scintigraphy in patients with lower gastrointestinal tract hemorrhage: effect of positive findings on clinical management. Acad Radiol. 2003 May; 10(5):497-501.
Score: 0.011
-
Prevalence of newly diagnosed sarcoidosis in patients with ventricular arrhythmias: a cardiac magnetic resonance and 18F-FDG cardiac PET study. Int J Cardiovasc Imaging. 2021 Apr; 37(4):1361-1369.
Score: 0.009
-
Computer-assisted Curie scoring for metaiodobenzylguanidine (MIBG) scans in patients with neuroblastoma. Pediatr Blood Cancer. 2018 12; 65(12):e27417.
Score: 0.008
-
Developing and validating a novel metabolic tumor volume risk stratification system for supplementing non-small cell lung cancer staging. Eur J Nucl Med Mol Imaging. 2018 11; 45(12):2079-2092.
Score: 0.008
-
Evaluation of parkinsonism and striatal dopamine transporter loss in patients with spinocerebellar ataxia type 6. J Neurol. 2016 Nov; 263(11):2302-2307.
Score: 0.007
-
A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer. 2015 Jul; 89(1):43-9.
Score: 0.006
-
Relationship between Overall Survival of Patients with Non-Small Cell Lung Cancer and Whole-Body Metabolic Tumor Burden Seen on Postsurgical Fluorodeoxyglucose PET Images. Radiology. 2015 Jun; 275(3):862-9.
Score: 0.006
-
FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer. Cancer Med. 2013 Aug; 2(4):545-52.
Score: 0.006
-
Advanced neuroimaging studies in a patient with brain metastases from transitional cell carcinoma of the bladder. J Neuroimaging. 2014 Jul-Aug; 24(4):429-31.
Score: 0.006
-
The utility of FDG-PET for assessing outcomes in oligometastatic cancer patients treated with stereotactic body radiotherapy: a cohort study. Radiat Oncol. 2012 Dec 18; 7:216.
Score: 0.005
-
Prognostic value of metabolic tumor burden on 18F-FDG PET in nonsurgical patients with non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2012 Jan; 39(1):27-38.
Score: 0.005
-
Interobserver variability among measurements of the maximum and mean standardized uptake values on (18)F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors. Acta Radiol. 2010 Sep; 51(7):782-8.
Score: 0.005
-
FDG-PET/CT findings of a metastatic pituitary tumor. Cancer Imaging. 2010 Mar 18; 10:114-6.
Score: 0.004
-
High prevalence of pineal cysts in healthy adults demonstrated by high-resolution, noncontrast brain MR imaging. AJNR Am J Neuroradiol. 2007 Oct; 28(9):1706-9.
Score: 0.004
-
Integrating PET and CT information to improve diagnostic accuracy for lung nodules: A semiautomatic computer-aided method. J Nucl Med. 2006 Jul; 47(7):1075-80.
Score: 0.003